|Chemical and physical data|
|Molar mass||244.331 g/mol g·mol−1|
|3D model (JSmol)|
Ro60-0213 (Org 35032) is a drug developed by Hoffmann–La Roche, which acts as a potent and selective agonist for the 5-HT2C serotonin receptor, with more than 100x selectivity over other closely related serotonin receptor subtypes, and little or no affinity at other receptors. It was developed as a potential antidepressant, but was discontinued from clinical development at an early stage due to toxicity concerns. However the high selectivity of Ro60-0213 for 5-HT2C makes it of continued interest for research into serotonin receptors.
- Leysen, D.; Kelder, J. (1998). "Ligands for the 5-HT2C receptor as potential antidepressants and anxiolytics". 29: 49–61. doi:10.1016/S0165-7208(98)80044-5. Cite journal requires
- "Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay". Mutagenesis. 13 (4): 397–403. July 1998. doi:10.1093/mutage/13.4.397. PMID 9717178.
- Shimada, I; Maeno, K; Kazuta, K; Kubota, H; Kimizuka, T; Kimura, Y; Hatanaka, K; Naitou, Y; et al. (2008). "Synthesis and structure-activity relationships of a series of substituted 2-(1H-furo2,3-gindazol-1-yl)ethylamine derivatives as 5-HT2C receptor agonists". Bioorganic & Medicinal Chemistry. 16 (4): 1966–82. doi:10.1016/j.bmc.2007.10.100. PMID 18035544.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|